Canadian regulators withdraw Shire drug on safety fears
Friday 11 February 2005
The sudden withdrawal of the drug, which is used to treat attention deficit hyperactivity disorder (ADHD), was caused by an order from Health Canada, the Canadian drug authority, after reports indicated that 14 children and six adults had died suddenly after taking regular doses of the drug. Of the deaths, 12 were due to strokes, two of which occurred in children.
The authority undertook a further study comparing Adderall with rival drugs for ADHD, which showed the incidence of adverse reactions that could lead to death was higher with Adderall than with other treatments. About 11,000 patients are now being advised to consult their doctors about finding alternative drugs.
Shares in Shire crashed 16 per cent on the news, as fears spread that the Food and Drug Administration (FDA) would take similar action in the United States.
The FDA, however, said that although it had seen the same data as Health Canada regarding the deaths, it does not believe the information gives rise to sufficient safety concerns to warrant revoking approval for Adderall. This helped the shares in the company slightly and they closed down 10 per cent at 577.5p.
Shire said it "strongly disagrees" with Health Canada's decision. Matthew Emmens, the chief executive, said: "We are surprised by this action. Shire remains confident in the safety and efficacy of Adderall."
The 20 deaths - which Health Canada said occurred outside the country - happened over 10 years, during which time 38 million prescriptions for Adderall had been written.
Frances Cloud, an analyst at Nomura, said: "These deaths were extremely rare. Since Canadian sales of Adderall were only $10m (pounds 5m), the financial impact of this decision is negligible. Were the FDA to remove approval, it would be disastrous for Shire, which obtains more than 40 per cent of its sales from this product. But this is extremely unlikely."
Tony Butler, at Lehman Brothers, said rivals such as the US drug maker Eli Lilly could benefit from Canada's move. "We view the US impact for [Lilly's ADHD treatment] Strattera could be positive, but not necessary imminent," he added.
The FDA said yesterday that it had evaluated the risk of sudden death with Adderall before giving it approval, but it does not believe the number of deaths reported is greater than the number of sudden deaths that would be expected to occur in the population.
It believes new labelling requirements it asked Shire to introduce in September, which beefed up warnings on the danger of taking the drug if the patient has heart problems, is adequate for the risks involved.
Adderall had been on sale in Canada for 12 months. It is not sold in Europe.
- 1 Katie Hopkins attacked me on Twitter — so I reported her to the police for inciting racial hatred
- 2 Google April Fools': company unveils backwards search engine and huggable digital assistant
- 3 I might be an MP, but that doesn't stop me fighting sexism with my breasts
- 4 April Fools' Day 2015: The best hoax news stories from around the internet
- 5 Gamers confess the worst things they've done in The Sims
Holborn fire: Chaos as 2,000 people evacuated to escape toxic smoke filling central London
University of Cambridge: Remains of 1,300 scholars are found under building
April Fools' Day 2015: The best hoax news stories from around the internet
April Fools' Day 2015 live: The best pranks and fake stories from around the world
Jeremy Clarkson 'could be given minder' ahead of a potential Top Gear return
Street preacher quoting from the Bible fined for calling homosexuality an 'abomination'
Katie Hopkins attacked me on Twitter — so I reported her to the police for inciting racial hatred
Woman filmed launching racist tirade against men on the Tube for speaking in 'own lingo'
David Cameron calls Labour 'hopeless, sneering socialists' while announcing 7-day NHS plans
Revealed: Putin's army of pro-Kremlin bloggers
Katie Hopkins reported to the police for race hatred by Labour MP Simon Danczuk after tweet about Pakistani men
iJobs Money & Business
£20000 per annum + commission: SThree: Sthree have an exciting opportunity for...
£18000 - £32000 per annum: Recruitment Genius: A Telesales Executive is requir...
£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...